Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
- Nakagawa K.
- Garon E. B.
- Seto T.
- Nishio M.
- Ponce Aix S.
- Paz-Ares L.
- Chiu C. -H.
- Park K.
- Novello S.
- Nadal E.
- Imamura F.
- Yoh K.
- Shih J. -Y.
- Au K. H.
- Moro-Sibilot D.
- Enatsu S.
- Zimmermann A.
- Frimodt-Moller B.
- Visseren-Grul C.
- Reck M.
- Chu Q.
- Cortot A.
- Pujol J. -L.
- Fabre E.
- Lamour C.
- Bischoff H.
- Kollmeier J.
- Kimmich M.
- Engel-Riedel W.
- Hammerschmidt S.
- Schutte W.
- Syrigos K.
- Ho J. C. M.
- Au K. -H.
- Ardizzoni A.
- Pasello G.
- Gregorc V.
- Del Conte A.
- Galetta D.
- Takahashi T.
- Kumagai T.
- Hotta K.
- Goto Y.
- Hosomi Y.
- Sakai H.
- Takiguchi Y.
- Kim Y. H.
- Kurata T.
- Yamaguchi H.
- Daga H.
- Okamoto I.
- Satouchi M.
- Ikeda S.
- Kasahara K.
- Atagi S.
- Azuma K.
- Aoe K.
- Horio Y.
- Yamamoto N.
- Tanaka H.
- Watanabe S.
- Nogami N.
- Ozaki T.
- Koyama R.
- Hirashima T.
- Kaneda H.
- Tomii K.
- Fujita Y.
- Seike M.
- Nishimura N.
- Kato T.
- Ichiki M.
- Saka H.
- Hirano K.
- Nakahara Y.
- Sugawara S.
- Kim S. -W.
- Min Y. J.
- Lee H. W.
- Kang J. -H.
- An H. J.
- Lee K. H.
- Kim J. -S.
- Lee G. -W.
- Lee S. Y.
- Alexandru A.
- Udrea A. A.
- Juan-Vidal O.
- Nadal-Alforja E.
- Gil-Bazo I.
- Ponce-Aix S.
- Rubio-Viqueira B.
- Alonso Garcia M.
- Felip Font E.
- Fuentes Pradera J.
- Coves Sarto J.
- Lin M. -C.
- Su W. -C.
- Hsia T. -C.
- Chang G. -C.
- Wei Y. -F.
- Su J.
- Cicin I.
- Goksel T.
- Harputluoglu H.
- Ozyilkan O.
- Henning I.
- Popat S.
- Hatcher O.
- Mileham K.
- Acoba J.
- Garon E.
- Jung G.
- Raj M.
- Martin W.
- Dakhil S.
DOIAbstract
Background: Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the approach is not widely implemented. RELAY assessed erlotinib, an EGFR tyrosine kinase inhibitor (TKI) standard of care, plus ramucirumab, a human IgG1 VEGFR2 antagonist, or placebo in patients with untreated EGFR-mutated metastatic NSCLC. Methods: This is a worldwide, double-blind, phase 3 trial done in 100 hospitals, clinics, and medical centres in 13 countries. Eligible patients were aged 18 years or older (20 years or older in Japan and Taiwan) at the time of study entry, had stage IV NSCLC, with an EGFR exon 19 deletion (ex19del) or exon 21 substitution (Leu858Arg) m...
Add to ORKG